Clinical Study Results
Research Sponsor: MedImmune, a wholly owned subsidiary of
AstraZeneca
Drugs Studied: Durvalumab, tremelimumab, and bevacizumab
Study Purpose: A study to learn about the safety of
durvalumab, tremelimumab, and
bevacizumab in participants with
advanced liver cancer
Protocol Number: D4190C00022
Thank you
Thank you for taking part in the clinical study for the study drugs durvalumab,
tremelimumab, and bevacizumab. Durvalumab is also called MEDI4736.
MedImmune, a wholly owned subsidiary of AstraZeneca, sponsored this study and
believes it is important to share the results of the study with the participants and
the public. An independent non-profit organization called CISCRP helped prepare
this summary of the study results for you.
If you participated in the study and have questions about the results, please speak
with the study doctor or staff at your study site.
1